Meridian Clinical Research, now part of Velocity Clinical Research, won the 2020 Vaccine Industry Excellence (ViE) award for Best Clinical Trial Site. The company was also part of Platinum Research Network, which won the ViE award for Best Clinical Trial Network.
“It’s incredible to earn these awards when vaccine trials are the industry’s priority and so visible in the public spotlight,” said Nicole Osborn, Meridian founder and CEO. “It reaffirms the quality of work our investigators and staff put forward every day, and the trust we’ve established with leading vaccine developers.”
The winners were announced at the virtual World Vaccine Congress typically held in Washington, D.C. The awards were decided by two rounds of voting and a final judgement by a scientific advisory board. Judges reviewed performance metrics, diversity of capabilities for vaccine trials, ongoing outcomes, and other factors to select a winner.
“In the past few years, we focused on providing fast startup, immediate enrollment, and scalability for our clients’ vaccine research programs,” said Osborn. “When COVID-19 vaccine trials began, we had the capabilities and reach when Sponsors and CROs needed it most.”
Earlier this year, Meridian principal investigators were the first in the U.S. to enroll patients into Phase II and III COVID-19 vaccine studies. Leaders of the Operation Warp Speed (OWS) program — including Moncef Slaoui, chief advisor, and General Gustave F. Perna, chief operating officer — visited Meridian’s internal medicine site in Savannah, GA.
